Dr. Shifeng S. Mao
Claim this profileAllegheny General Hospital
Studies Bladder Cancer
Studies Transitional Cell Carcinoma
4 reported clinical trials
9 drugs studied
Area of expertise
1Bladder Cancer
Stage IV
HER2 positive
Stage III
2Transitional Cell Carcinoma
Stage IV
HER2 positive
Stage III
Affiliated Hospitals
Clinical Trials Shifeng S. Mao is currently running
Disitamab Vedotin + Pembrolizumab vs Chemotherapy
for Bladder Cancer
This study will enroll participants with urothelial cancer (UC). UC can include cancer of the bladder, kidney, or the tubes that carry pee through the body (ureter, urethra). This study will try to find out if the drugs disitamab vedotin with pembrolizumab works better than platinum-containing chemotherapy to treat patients with UC. This study will also test what side effects happen when participants take these drugs together. A side effect is anything a drug does to the body besides treating the disease. Participants in this study will have cancer that has spread through the body (metastatic) or spread near where it started (locally advanced). In this study, there are 2 different groups. Participants will be assigned to a group randomly. Participants in the disitamab vedotin arm will get the study drug disitamab vedotin once every two weeks and pembrolizumab once every 6 weeks. Participants in the standard of care arm will get gemcitabine once a week for 2 weeks with either cisplatin or carboplatin once every 3 weeks.
Recruiting2 awards Phase 3
Immunotherapy + Targeted Therapy
for Genitourinary Cancers
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.
Recruiting1 award Phase 221 criteria
More about Shifeng S. Mao
Clinical Trial Related7 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Shifeng S. Mao has experience with
- Gemcitabine
- Carboplatin
- Cisplatin
- Nivolumab
- Ipilimumab
- Disitamab Vedotin
Breakdown of trials Shifeng S. Mao has run
Bladder Cancer
Transitional Cell Carcinoma
Cancer
Prostate Cancer
Prostate
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Shifeng S. Mao specialize in?
Shifeng S. Mao focuses on Bladder Cancer and Transitional Cell Carcinoma. In particular, much of their work with Bladder Cancer has involved Stage IV patients, or patients who are HER2 positive.
Is Shifeng S. Mao currently recruiting for clinical trials?
Yes, Shifeng S. Mao is currently recruiting for 2 clinical trials in Pittsburgh Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Shifeng S. Mao has studied deeply?
Yes, Shifeng S. Mao has studied treatments such as Gemcitabine, Carboplatin, Cisplatin.
What is the best way to schedule an appointment with Shifeng S. Mao?
Apply for one of the trials that Shifeng S. Mao is conducting.
What is the office address of Shifeng S. Mao?
The office of Shifeng S. Mao is located at: Allegheny General Hospital, Pittsburgh, Pennsylvania 15212 United States. This is the address for their practice at the Allegheny General Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.